



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Tugrul T. Kararli, *et al.*  
Serial No: 10/031,898  
Filed: December 9, 2002  
Title: Cyclooxygenase-2 Inhibitor Compositions Having Rapid Onset of  
Therapeutic Effect  
Confirmation No: 8229  
Group Art Unit: 1615  
Examiner: Carlos A. Azpuru  
Attorney Ref: 6794S-000005/USC  
Pharmacia Ref: 3267/1A/US  
Pfizer Ref: 31214/USA

October 12, 2005

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449 and copies of all documents listed on that form.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this Supplemental Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.5, but by listing such documents are not admitting that such documents are necessarily relevant or prior art.

Applicants intend no representation that the listed documents represent the results of a complete

EV 726255276 U

10/12/2005 HDEST01 00000035 10031898 180.00 0P 02 FC:1806

search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b), and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

Applicants make no representation as to the accuracy of any translation provided with this Information Disclosure Statement.


Applicants request early and favorable consideration.

\* \* \* \* \*

A check in the amount of \$180.00 is enclosed in connection with this Supplemental Information Disclosure Statement. Applicants believe that they do not owe any additional fee in connection with this Information Disclosure Statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.


Respectfully submitted,

  
\_\_\_\_\_  
James E. Davis, PTO Reg. No. 47,516  
Harness, Dickey & Pierce, P.L.C.  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

Supplemental Information Disclosure Statement

Appl. No. 10/031,898


October 12, 2005



CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **October 12, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.

JED/PML  
Enclosures

  
James E. Davis, PTO Reg. No. 47,516